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Abstract
Adipokines (adipose tissue cytokines) are polypeptide factors secreted by adipose tissue in a highly regulated
manner. The ‘classical’ adipokines (leptin, adiponectin, and resistin) are expressed only by adipocytes, but other
adipokines have been shown to be released by resident and infiltrating macrophages, as well as by components of
the vascular stroma. Indeed, adipose tissue inflammation is known to be associated with a modification in the
pattern of adipokine secretion. Several studies indicate that adipokines can interfere with hepatic injury associated
with fatty infiltration, differentially modulating steatosis, inflammation, and fibrosis. Moreover, plasma levels of
adipokines have been investigated in patients with nonalcoholic fatty liver disease in order to establish correlations
with the underlying state of insulin resistance and with the type and severity of hepatic damage. In this Forum
article, we provide a review of recent data that suggest a significant role for oxidative stress, reactive oxygen species,
and redox signaling in mediating actions of adipokines that are relevant in the pathogenesis of nonalcoholic fatty
liver disease, including hepatic insulin resistance, inflammation, and fibrosis. Antioxid. Redox Signal. 15, 461–483.
Adipokines
White adipose tissue, the most abundant in adults, hasthree main functions: 1) storage of energy in the form of
triglycerides; 2) hydrolysis of triglycerides to provide free
fatty acids to support the energy needs of tissues, especially
skeletal muscle; 3) release of adipokines (or adipocytokines).
Data accumulated over the last two decades have shown that
the functions of adipose tissue are not limited to energy
storage, but extend to fundamental processes such as me-
tabolism, immune response, tissue regeneration, wound
healing, and cancer. In this context, the relations between the
liver and adipose tissue are particularly close, and represent
the result of a diversification of functions that are present in
the same tissue in lower organisms (72). The interest in adi-
pose tissue pathophysiology has grown along with the dra-
matic increase in the prevalence of obesity (116). Obesity is a
component of the metabolic syndrome and thus a major risk
factor for the development of nonalcoholic fatty liver disease
(NAFLD) and for progression to advanced fibrosis and cir-
rhosis in the context of nonalcoholic steatohepatitis. None-
theless, adipose tissue expansion has an impact on liver
diseases in general, as cirrhosis is more prevalent in obese
patients (139), and obesity favors the appearance of severe
fibrosis in chronic liver diseases (3), and confers a higher risk
of liver cancer (28).
Adipokines (adipose tissue cytokines) are polypeptide fac-
tors which are expressed significantly, although not exclu-
sively, by adipose tissue in a regulated manner. In adipose
tissue, adipokines modulate adipocyte differentiation and
regulate lipid accumulation through autocrine mechanisms.
This feature has a clear relevance in obesity that is associated
with adipose tissue inflammation, and has been linked to the
appearance of insulin resistance and to the metabolic and
cardiovascular complications of the metabolic syndrome (153).
An additional factor that has received considerable attention in
the pathophysiology of adipose tissue is the role of ectopic fat,
that is, adipose tissue expansion at sites different from sub-
cutaneous adipose tissue, such as in the omentum (visceral fat)
or around the heart (epicardial or mediastinal fat). Ectopic fat
is more likely to undergo inflammation and to contribute to
the pathogenesis of obesity-related disorders (72).
Only one-third of adipose tissue is composed of adipocytes,
the rest being stromal cells, macrophages, fibroblasts, and
monocytes, all of which contribute to adipokine production.
The ‘classical’ adipokines are those primarily expressed by
adipocytes, namely leptin, adiponectin, and resistin, but an
expanding group of newly identified adipokines is currently
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being investigated and some of them may be expressed by
vasculo-stromal cells (117).
Leptin has been the first adipokine to be identified, as the
circulating product of the obese (ob) gene, which is expressed by
adipose tissue and at several other sites (129). Leptin receptors
belong to the class I of cytokine receptor superfamily, and six
isoforms have been identified. The long receptor, ObRb, me-
diates most of the biological effects of this adipokine, and is
able to fully activate intracellular signaling via the Jak-2/Stat3
pathway (129). Secretion of leptin is directly proportional to
the fat mass, and provides anti-obesity signals, regulating food
intake and energy expenditure in conditions of energy excess,
through hypothalamic pathways. This action is reflected by
the phenotype of ob/ob mice, which lack functional leptin and
are obese and hyperphagic. In addition, leptin stimulates
wound repair, modulates innate and adaptive immunity, and
regulates hematopoiesis and reproduction.
Adiponectin circulates as a full-length molecule assembled
in complexes of different molecular weight, or as the isolated
C-terminal globular domain (85). Adiponectin binds at least
two specific receptors, AdipoR1 and AdipoR2, (38) which
belong to the seven transmembrane domain receptor family
but are not coupled to G protein. AdipoR1 is expressed in
several tissues and in skeletal muscle, while AdipoR2 is
mostly expressed by hepatocytes. Binding experiments in-
dicate that AdipoR1 interacts preferentially with the glob-
ular domain, and its main downstream effector is the
AMP-activated protein kinase (AMPK). AdipoR2 binds with
similar affinity both full-length and globular adiponectin and
signals predominantly via activation of peroxisome proliferator-
activated receptor-a (PPARa).
Adiponectin concentrations are inversely correlated with
fat mass, and are downregulated in patients with obesity (85).
Moreover, adiponectin exerts insulin sensitizing effects and
acts as an anti-inflammatory molecule. Conversely, inflam-
mation is a potent inhibitor of adiponectin release, and adi-
pose tissue inflammation is considered one of the main
mechanisms underlying reduced plasma levels in obesity.
Resistin belongs to a family of small cysteine-rich secretory
proteins, named FIZZ (found in inflammatory zone) or
RELMs (resistin-like molecules) (166). In rodents, resistin is
highly expressed by adipose tissue and circulating levels are
increased during diet-induced or genetic obesity (165), where
resistin may be a link between obesity and insulin resistance
(137). Reduced hepatic glucose production in the absence of
resistin is also associated with higher hepatic AMPK activa-
tion (14). In humans, the biology of resistin is less defined, and
most studies demonstrate that resistin is expressed predomi-
nantly by bone marrow-derived cells and inflammatory cells
(128). In human monocytes, resistin expression is increased by
treatment with proinflammatory cytokines in vitro and cir-
culating levels of resistin are higher in different conditions of
inflammation.
Adipokines, Oxidative Stress, and Hepatic
Insulin Resistance
Insulin signaling pathways and the hepatic control
of glucose and lipid metabolism
Hepatocytes, together with myocytes and adipocytes,
represent a major cellular target for insulin by expressing a
high number of insulin receptor (IR) molecules on their
plasma membrane (32, 175). The most relevant aspects of the
insulin signaling network will be briefly summarized herein
and in Figures 1 and 2, dedicated to the overall control of
insulin signaling (110, 123, 175, 187) and related cellular re-
sponses (175), respectively. Insulin, binding to one of the two
isoforms of its tetrameric receptor (IRA or IRB, having different
affinity for insulin and IGF1), activates signaling by leading to
de-repression of tyrosine-kinase (TK) activity of the two in-
tracellular b-subunits and to trans-phosphorylation of specific
tyrosine residues, resulting in a further increase in kinase
activity.
Following activation of IR (and IGFR1), the insulin signal-
ing network, which is carefully controlled by a number of
mechanisms (illustrated in Fig. 1, Ref.175), proceeds through
phosphorylation of intracellular substrate proteins, including
the six different isoforms of insulin receptor substrate (IRS)
proteins (IRS 1–6), and various isoforms of Src homology-2
(SH2)-containing proteins (175), that in turn, mediate the
binding of downstream effectors. Best characterized and most
relevant for insulin signaling are IRS1 and IRS2 (widely dis-
tributed, major isoforms in hepatocytes), IRS3 (mostly re-
stricted to adipose tissue and brain), and IRS4 (expressed in
embryos and cell lines). Phosphorylated IRS serve as docking
platforms for signaling proteins containing SH2, including: 1)
the regulatory subunit of phosphatidylinositol 3-kinase
(PI3K) or the adaptor Grb2, which activate the Ras/MAPK
signaling pathway; 2) enzymes like SH2-domain containing
tyrosine phosphatase-2 (SHP2), cytoplasmic tyrosine kinases,
and the Ca2+ -ATPases SERCA1 and 2.
IR activation, through the involvement of IRS, results in the
engagement of two main divergent pathways (Fig. 2; 175): 1)
PI3K, leading to activation of PKB/Akt or atypical PKC iso-
forms, a pathway which mediates the main metabolic actions
of insulin with a complexity that is exacerbated by the existence
of multiple isoforms of IRS, PI3K, (regulatory and catalytic) and
Akt (reviewed in Ref. 175); 2) the MAP kinase pathway, leading
to cell proliferation, survival, and differentiation.
In hepatocytes (67, 99, 175), IRS-1 has a major role in han-
dling increased glucose levels in the fed state and is involved
in the control of glycogen synthesis and lipogenesis. Glucose,
entering hepatocytes through the specific GLUT-2 trans-
porter, is then directed to the glycolytic pathway and ATP
production in order to fulfill energy requirements and re-
plenish glycogen stores. Excess glucose can be diverted to
lipogenesis, and insulin can then act as a potent stimulator
of lipogenic pathways by operating mainly through sterol
regulatory element binding protein-1 (SREBP-1) and the
glucose-responsive transcription factor carbohydrate response
element-binding protein (ChREBP) (135, 178). IRS2 is more
involved in the fasting state, when it is upregulated to favor
the action of insulin, limiting the expression of gluconeogenic
enzymes such as glucose-6-phosphatase or phosphoenolpyr-
uvate carboxykinase (PEPCK) and then the hepatic produc-
tion of glucose and its export by the GLUT2 transporter.
Besides the opposing effects of insulin and glucagon on fatty
acid mitochondrial oxidation, insulin signaling limits gluca-
gon-stimulated gluconeogenesis by means of Akt–dependent
phosphorylation of the forkhead box–containing protein O
subfamily-1 (FOXO1) transcription factor. When phosphory-
lated, FOXO1 is segregated into the cytoplasm and degraded
by the proteasome pathway, preventing nuclear translocation
and regulation of PEPCK expression (99, 135).
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As far as PI3K and Akt are concerned, IR- or IGF1R-related
PI3K involvement results from direct interaction with phos-
phorylated substrate proteins, including IRS, leading to
phosphatydylinositol-3-phosphate (PIP3) generation and, in
turn, PIP3-mediated activation of different Akt isoforms.
Apart from negative feedback control on insulin signaling by
PI3K (see Fig. 1), PIP3 recruits phosphoinositide-dependent
kinase-1 and Akt isoforms at the plasma membrane, where
the different Akt isoforms (Akt-1, - 2, and - 3) are phos-
phorylated on tyrosine and serine residues by PDK1 and
PDK2, possibly through formation of a complex with the
mammalian target of rapamycin (mTOR). Phosphorylation
of Akt in turn confers the ability to phosphorylate a series of
downstream signaling targets that mediate major effects of
insulin signaling on glycogen synthesis, gluconeogenesis, and
protein synthesis (175).
Hepatic insulin resistance and its effects
on glucose and lipid metabolism
It has been proposed that hepatic insulin resistance repre-
sents the single major pathophysiologic derangement in the
metabolic syndrome (95) as well as a major culprit in the de-
velopment of type II diabetes (59, 184). Along these lines, non-
alcoholic fatty liver disease (NAFLD) is strongly associated with
both hepatic and adipose tissue insulin resistance, and reduced
whole body insulin sensitivity (26, 115, 156). Moreover, NAFLD
patients also exhibit a reduction in fatty acid oxidation, a feature
which is likely to reflect a decreased uptake and utilization of
glucose as a source of energy (26). All these findings have led to
the suggestion (see Ref. 135) that insulin resistance may repre-
sent an intrinsic defect in NAFLD and that the decreased insulin
responsiveness at the level of adipocytes may significantly
FIG. 1. Insulin signaling
pathway and its regulatory
mechanisms. The figure
shows the major steps in insu-
lin-mediated signaling follow-
ing interaction of insulin with
the tetrameric insulin receptor
(IR) complex at the plasma
membrane level, together with
the major inhibitory mecha-
nisms and the cross-talk with
signaling pathways elicited by
cytokines and growth factors,
including TNFa and IGF-1.
Following ligand–receptor in-
teraction, IR activation is
tightly regulated by several
negative mechanisms that in-
clude (175): a) tyrosine phos-
phatases, particularly PTP1B
that directly interacts with IR
to dephosphorylate critical ty-
rosine residues; b) proteins that
sterically block IR function
either by preventing its inter-
action with intracellular sub-
strate proteins or by modifying
its kinase activity, including
suppressor of cytokine signaling (SOCS)-1 and - 3, which are known to be upregulated under conditions of insulin resistance; and
c) ligand-stimulated internalization and degradation of IR, a process which again occurs under conditions of insulin resistance.
Upon activation, IR as well as IGF1R can phosphorylate intracellular substrate proteins that mediate the binding of downstream
effectors, the most relevant being the isoforms of insulin receptor substrate (IRS) proteins, leading then to the activation of PI3K and
PKB/Akt. PI3K acts as a negative regulator of insulin signaling on the basis of at least three distinct mechanisms: 1) efficiency of
insulin signaling critically depends on the stoichiometry of the p85 regulatory subunit to the catalytic heterodimer (123); 2)
sequestration of IRS/PI3K complex into signaling-silent compartments (i.e., incapable of generating PIP3) provides negative
regulation (110); 3) the recruitment of inhibitory proteins that interact with monomeric p85a regulatory subunits. This leads to either
PIP3 degradation by phospholipid phosphatases like PTEN or through negative regulation of insulin signaling by activation of JNK
activity. In particular, JNK activation, which is also induced by TNF, operates its inhibitory action phosphorylating IRS1 and IRS2
on serine residues (175, 187). A very close mechanism has been described for IjB kinase beta (IKKb) that controls the activation of
NF-jB; once activated, IKKb phosphorylates IRS-1 on Ser307 residue, resulting in inhibition of insulin action (63). Further mech-
anisms leading to inhibition of insulin signaling are operated through suppressors of cytokine signaling (SOCSs), regulated by
several cytokines, including IL-6 and leptin, and upregulated in conditions of insulin resistance (135, 175, 178). SOCS proteins act by
linking IRS to ubiquitin-mediated degradation pathways and activating SREBP1, thus favoring lipogenesis (154, 188). Similar
SOCS-mediated mechanisms may operate in insulin resistance associated with chronic HCV infection, as HCV core protein can
upregulate SOCS and then promote degradation of IRS1 and IRS2 (91).
Akt is negatively regulated by the action of the phosphatases Src-homology-2 domain-containing inositol phospatase-2A (PP2A)
and the pleckstrin-homology (PH) domain leucine-rich-repeat protein phosphatase (PHLPP). Other details can be found in the text.
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contribute to hepatic steatosis, providing an excess of FFA flux
to the liver. According to the scope of this Forum article, we will
focus on the pathophysiology of impaired glucose and lipid
metabolism at hepatic level, considering the liver as a major site
of insulin action, concentrating our attention on those adipo-
kine- and/or oxidative stress-related mechanisms or molecular
derangements associated with hepatic insulin resistance that are
also likely to favor the development of liver steatosis.
The major and well-established general problem with in-
sulin resistance is a significant decrease in the ability of insulin
to stimulate glucose disposal and inhibit hepatic glucose
production (86). It has been suggested (135) that humans can
accumulate the excess of FFA as TG stores as a consequence of
a limited number of events, including: a) reduction of fatty
acid oxidation; b) increased de novo lipogenesis; c) increased
fatty acid hepatic influx; d) impaired fatty acid and TG efflux
from the liver. Moreover, peripheral (i.e., skeletal muscle and
adipose tissue) insulin resistance results in an increased flux of
FFA towards the liver and then favoring hepatic steatosis
(135). Finally, as we will detail later, one should remember
that hepatic steatosis itself can further result in insulin resis-
tance and exacerbate whole body insulin resistance (92, 93).
Adipokines, oxidative stress and inflammation:
molecular links to hepatic insulin resistance
A derangement or loss of insulin signaling at the hepato-
cyte level has been proposed to lead to severe insulin resis-
tance and progressive hepatic dysfunction, and is considered
a major mechanism for impaired glucose handling and in-
creased fat storage, not only for the liver but also for skeletal
muscle and adipose tissue (124). Here we will focus on the role
of the adipokines and oxidative stress, and particularly on the
role of intracellular levels of reactive oxygen species (ROS),
both as mediators and modulators of critical signaling event.
An extensive introduction on ROS, antioxidant defenses, and
principles of redox signaling is of course out of the scope of the
present Forum article and the interested reader can refer to
more comprehensive and specialized reviews (37, 132, 177) as
well as to Figures 3–6 and related legends which offer, in this
connection, a synthetic overview of most relevant concepts. In
this review we will try instead to emphasize established and
putative redox mechanisms that may be based on ROS or
other oxidative stress-related reactive intermediates gener-
ated within the cell or entering target cells (mainly hydrogen
peroxide and 4-hydroxy-2,3,-nonenal or HNE), that are gen-
erated in a pro-oxidant microenvironment.
Intracellular oxidative stress can occur in fat-laden hepato-
cytes. As reviewed elsewhere (133, 135) increased hepatocyte
levels of FFAs in NAFLD/NASH are considered a relevant
mechanism leading to hepatocyte injury: a) FFAs can directly
induce hepatocyte apoptosis and stimulate production of TNF,
which in this context should also be considered as an adipo-
cytokine; b) FFAs can increase Fas ligand binding to the Fas
receptor (CD95) in steatotic hepatocytes, leading to apoptosis;
c) excess of FFAs in hepatocytes leads to impaired mitochon-
FIG. 2. Insulin signaling
and related metabolic or
functional responses. IR ac-
tivation, through the involve-
ment of IRS, results in the
engagement of two main and
divergent pathways (175).
First, the MAP kinase path-
way, particularly Ras/Erk,
leads to cell proliferation, sur-
vival, and differentiation. Sec-
ond, the PI3K pathway leads
to activation of PKB/Akt or
atypical PKC isoforms, which
mediates the main metabolic
actions of insulin. Activation/
phosphorylation of PKB/Akt,
in particular, confers the abil-
ity to phosphorylate a series of
downstream signaling targets
that mediate major effect of
insulin signaling on glycogen
synthesis, gluconeogenesis,
and protein synthesis: a) gly-
cogen-synthase kinase 3
(GSK3), that when phosphor-
ylated is inactive on glycogen
synthase, leading to increased
glycogen synthesis; b) FOXO1,
a transcription factor which is phosphorylated on Ser256 and sequestered in the cytoplasm, thus preventing its action on genes
related to gluconeogenesis like PEPCK; c) Akt substrate of 160 kDa (AS160), which in turn controls the activity of Rab-GTpase
activating protein and translocation of glucose transporters (e.g., GLUT4) to plasma membrane; d) tuberin or tuberous sclerosis
complex-2 (TSC2) which is complexed with TSC-1: phosphorylation of TSC1/2 by PKB/Akt removes the TSC1/2-mediated
inhibitory control on the mTOR pathway, leading to phosphorylation of mTOR downstream signaling substrates like the
eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) and p70 ribosomal protein S6 kinase (p70S6K), leading to
upregulation of protein synthesis.
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drial or peroxisomal oxidation of FFAs, eventually leading to
generation of ROS and products of lipid peroxidation, mainly
HNE, which in turn may cause cell injury and death; d) induc-
tion of ER stress and of the ’unfolded protein response’, which
potentially results in the induction of caspase-dependent cell
death involving mitochondria (71, 133, 135, 136, 178). It
should be noted that all these mechanisms are intrinsically
related to increased intracellular ROS generation (Fig. 3).
A first redox-dependent mechanism involved in insulin
resistance is based on the activation of c-jun N-terminal kinase
( JNK). Both TNF and FFAs are powerful modulators of the
activity of two kinases, namely JNK and IjB kinase (IKK),
which couple inflammatory and metabolic signals (133, 178).
Interaction of TNF with its receptor results in activation of
NADPH oxidase, mitochondrial outer membrane depolar-
ization, and FFA-related mitochondrial dysfunction, ER stress
FIG. 3. Intracellular generation of ROS in mammalian cells. ROS can be generated within living cells by the following
major sources: 1) Mitochondria: Approximately 1%–5 % of the electrons flowing through the electron transport chain can be
diverted to form O2
 - at the level of Complex I (NADH/ubiquinone oxidoreductase) and Complex III (ubiquinol/cyto-
chrome-c oxidoreductase). O2
 - is then converted by a mitochondrial isoform of superoxide dismutase (mtSOD) into H2O2
that can cross mitochondrial membranes and then reach the cytoplasm. 2) Plasma membrane NADPH oxidase (NOX): This
multi-subunit complex is expressed by professional phagocytic cells (macrophages, neutrophils, and eosinophils) as well as
by a number of nonphagocytic cells playing a critical role in human diseases. NOX of professional phagocytes and of
nonphagocytic cells are similar in their structure being formed by two membrane bound components (p22phox and
gp91phox/Nox2 or another member of the NOX family of protein) forming the flavocytochrome b558, and four cytosolic
components (p40 phox, p47phox, p67phox, and the GTPase Rac1/2), that following stimulation, are recruited to the plasma
membrane where they interact with Cyt b558 leading to increased activity and then generation of O2
 - that is then converted
into H2O2. Where redox signaling is concerned, the major difference is that nonphagocytic NOX, which is constitutively
active and produce a very low level of ROS, can significantly increase both activity and ROS generation in response to growth
factors, cyto- and chemokines, and other conditions. 3) Several enzymes involved in redox reactions: Several enzymes are
able to generate ROS (mostly O2
 - that is rapidly converted by a SOD isoform into H2O2) during their catalytic activity,
including several oxidases, peroxidases, cytochromes, mono- and di-oxygenases, with the following being the most relevant
examples: isoforms of the cytochrome P450 superfamily, involved in metabolism of endo- and xenobiotics, including ethanol,
steroid hormones, drugs, and chemotherapeutics; xanthine oxidase; the isoforms of cyclooxygenase; peroxisomal oxidases,
that can generate directly H2O2 when metabolizing various substrates (glycolate-, D-amino-, ureate-, fatty acid-CoA-, and L-
a-hydroxyacid oxidases); lysyl oxidase that again generate H2O2 when catalyzing the formation of aldehyde precursors of
cross-links in collagen and elastin; 5-lipoxygenase, a mixed function oxidase involved in the synthesis of leukotrienes from
arachidonic acid in response to stimuli that are also able to stimulate NOX, particularly growth factors and cytokines.
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and/or increased activity of cytochrome P450 isoforms like
CYP2E1 and CYP3A (Fig. 2). On the other hand, ROS can
activate JNK (177, 196) either through activation of the up-
stream apoptosis-stimulated kinase 1 (ASK) or inactivation of
specific JNK-phosphatases (177, 196). Similarly, HNE has
been shown to interact directly with JNK, leading to its acti-
vation (133). In the context of hepatic insulin resistance, acti-
vation of JNK, and particularly of JNK-1, leads to increased
phosphorylation of IRS1 on serine 307, preventing its binding
to the IR and propagation of insulin signaling (4, 73, 185).
Upregulation of this inhibitory mechanism in association with
insulin resistance should be considered as an exacerbation of a
negative feed-back mechanism for the insulin signaling
pathway (175), since insulin itself is able to activate JNK and
FIG. 4. Simplified scheme of redox signaling induced by increase in intracellular levels of ROS. Under physiological
conditions, cells and tissues of aerobic organisms have to face relatively low amount (steady-state levels) of ROS, free radicals,
and other reactive intermediates that are the result of a dynamic balance between the rate of their generation and the rate of
their removal by one or more of defensive antioxidant systems (see Fig. 5), including highly specialized enzymes (catalase,
thioredoxins, SODs, and GPXs), naturally occurring antioxidants (GSH, vitamin E, b-carotene, ascorbate, urate, and many
others) as well as by amino acids, peptides, and proteins. Under these conditions, there is no significant unbalance of pro-
oxidants vs. antioxidant defenses and thus no response by means of a redox signaling.
Whenever redox homeostasis is significantly disturbed, by an increase in ROS generation (whatever the source, intra- or
extracellular), by a decrease in one or more antioxidants, or by a change in the thiol/disulfide redox state, redox signaling can
be elicited. This can potentially lead to at least three different scenarios in which the difference is made primarily by the
absolute levels of ROS and other reactive species reached within the cell as well as by the temporal length of the alteration. If
the starting stimulus/condition is able to induce a relatively low and transient (i.e., time limited) increase in intracellular
levels of ROS and other reactive mediators, then also the shift in redox balance will be limited and redox signaling will
operate through defined redox-sensitive signaling pathways and transcription factors to upregulate mainly transcription of
genes able to encode for products that will reset in the due time redox homeostasis (for example, antioxidant enzymes, Trxs
and Glrxs, cystine transport system to sustain genesis of GSH).
However, in conditions of extensive acute tissue injury as well as in tissues undergoing persisting injury, chronic in-
flammation, and chronic wound healing, levels of ROS and other related reactive intermediates or reactions (produced within
the ‘‘target cells’’ or by extracellular sources, such as by inflammatory or damaged cells) may be very high and/or persistently
increased within the cell to overcome antioxidant defenses and/or antioxidant response. If levels of ROS and related reactive
intermediates are very high, this will lead to irreversible injury and necrotic—or apoptotic—type of cell death. Alternatively,
when levels of oxidative stress are significantly high but not overtly able to induce irreversible cell damage, as in chronic
inflammatory diseases, cells and/or tissues may still reach an altered equilibrium characterized by a shift of the intracellular
redox state to higher levels of ROS and a chronically dysregulated state in which redox signalling is upregulating different
patterns of gene expression and cell responses, then contributing to the progression of the disease.
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FIG. 5. Synopsis of major antioxidant defenses in a mammalian cell. Antioxidant defenses relies on the sum of those
mechanisms that nature has developed to protect biological materials from ROS and other oxidants and those designed to
protect them from lipid peroxidation. In order to simplify concepts, antioxidant defenses may be differentiated into two major
(although inter-related) categories, separating defenses affording protection versus ROS and other oxidants from those
mainly offering protection against lipid peroxidation. Within the first category we can include the following class of defenses:
1. Antioxidant enzymes. This definition includes a group of very specific enzymes such as catalase, glutathione peroxidase
(GPX) isoforms, and superoxide dismutase (SOD) isoforms. Catalase and GPX isoforms are responsible for the removal
of hydrogen peroxide but also of other organic hydroperoxides, whereas SOD isoforms operate by transforming su-
peroxide into hydrogen peroxide. Major reactions of these enzymes are described.
2. Small molecules. This definition applies to several molecules but by far the most relevant are: a) ascorbic acid (vitamin C),
a molecule that can act as an electron donor and then as a reducing agent; ascorbate can also scavenge (i.e., interact
directly with) OH; b) reduced glutathione (GSH) that is a hydrosoluble tripeptide able to act as substrate for an enzyme
able to remove H2O2 like GPX, as a scavenger of OH and singlet oxygen, or as a low molecular weight thiol in
regenerating oxidized –SH groups of proteins; in the figure, the essential reaction of GSSG reductase, designed to
recover GSH, is also shown; c) uric acid, present in blood plasma, that has been reported to scavenge singlet oxygen,
OH, and peroxy radicals.
3. Protection by sequestration of metal ions. Transition metal ions such as iron and copper are able to lead to generation of
very reactive species from less reactive ones. Then a number of metalloproteins such as ferritin, transferrin, me-
tallothionein, and lactoferrin can be seen not only as relevant for their respective role in metal homeostasis but also as
molecules that by ‘‘sequestering’’ redox active metal ions may prevent ROS production via the Fenton reaction.
4. Thioredoxin and glutaredoxin systems. Thioredoxins (Trxs), described in the figure, are small proteins that have a catalytic
site containing two cysteine residues which can be oxidized reversibly to form disulfide bridges. They can undergo
NADPH-dependent reduction by the enzyme thioredoxin reductase, and in turn they can reduce oxidized cysteine
groups on proteins. These proteins, according to this intramolecular disulfide–thiol exchange, can act as hydrogen
donors contributing to the control of redox state and redox signaling (for example, by affecting the regulation of kinases
or transcription factors forming with them heterodimers).
Glutaredoxins (Glrxs) also belong to the thioredoxin superfamily of thiol/disulfide exchange proteins and in biological
systems serve as reductants of protein–SG mixed disulfides and. similarly to what is described for thioredoxin system the
glutaredoxin system (composed of Glrx isoforms, by glutathione reductase, GSH, and again NADPH) are also involved in
redox signaling.
Where protection from lipid peroxidation is concerned, two classes of antioxidants can be described:
1. Primary antioxidants, also often defined as ‘‘free radical scavengers’’ because they are able to interact directly with, and/
or to block the initiating free-radical (as for example OH); examples are urate (able to scavenge peroxy- and alkoxy
radicals as well as HOCl), and glucose (able to scavenge OH with a rate constant similar to that of mannitol).
2. Secondary or chain breaking antioxidants, (a-tocopherol or vitamin E being the prototype) which are able to intercept
radical intermediates produced during on-going lipid peroxidation such as peroxyl- or alkoxyl-radicals, then preventing
(i.e., ‘‘breaking’’) the perpetuation of hydrogen abstraction in the chain reaction.
ADIPOKINES, REDOX SIGNALING, AND NAFLD 467
other kinases which phosphorylate IRS on serine residues (see
Fig. 1). However, to emphasize the multiple role of redox
signaling, one should remember that in parallel, insulin has
been shown also to activate NADPH oxidase, leading to a
transient increase in ROS generation that through inhibition
of PTP1B transiently enhances insulin signaling (112).
The redox sensitivity of JNK1 is likely to be critical: JNK
activation not only prevents interaction of the IR with serine-
phosphorylated IRS proteins but also results in caspase acti-
vation and induction of apoptosis (41). Moreover, JNK1 is
likely also to control AP-1-dependent transcription, increas-
ing the expression of proinflammatory cytokines and further
contributing to JNK activation. JNK may have also a role in
activation of the SREBP1 pathway, known to be involved in
lipogenesis, which is increased in the presence of insulin re-
sistance, while it should theoretically be decreased (64, 147).
Several explanations have been proposed for this apparent
paradox, including: a) the pathway leading to SREBP-1 acti-
vation may remain sensitive to insulin; b) the activation of
lipogenesis by SREBP-1 and ChREB is sensitive to insulin as
well as to high glucose levels; c) SREBP-1 can be activated by
an insulin-independent mechanism related to ER-stress, that
develops in liver steatosis (57, 83); d) SREBP-1 can be also
activated by TNF as an additional contributory mechanism to
increased hepatic lipogenesis (103).
Finally, JNK1 may have an additional role in regulating the
expression and/or nuclear translocation of FOXO1, which is
involved in gluconeogenesis. In this connection, insulin re-
sistance results in a decrease of glycogen storage in hepato-
cytes in the postprandial state and in increased hepatic
production of glucose (gluconeogenesis) in the fasting state
(147). Data in experimental models indicate that fatty liver
may directly induce hepatic insulin resistance by stimulating
gluconeogenesis and activating PKC-e and JNK-1, which may
in turn impair the ability of insulin to activate glycogen syn-
thase (144). Inhibition of hepatic glucose output by insulin
involves Akt-dependent phosphorylation of FOXO1, a tran-
scription factor controlling the expression of G6PC and
FIG. 6. Generation of intracellular reactive oxygen species and related consequences in fat-laden hepatocytes. In the
peculiar hepatic milieu of a NAFLD/NASH patient, reactive oxygen species (ROS) can be generated within fat-laden
hepatocytes by a number of mechanisms that, pertinent to this review, may include the following: 1) Activation of NADPH
oxidase that is known to parallel interaction of several cytokines to their cognate receptors, including also TNFa; 2) activation
of 5-LOX by adiponectin following interactions with its receptor; 3) impairment of mitochondrial b-oxidation of free fatty
acids (FFAs); 4) impairment of peroxisomal oxidation of FFAs; 5) induction of endoplasmic reticulum (ER) stress by increased
intracellular levels of FFAs and/or related upregulation of CYP2E1 and CYP3A isoforms of the cytochrome P450 family. The
scheme, that also indicates major steps of FFAs induced, ER stress-related UPR response, recapitulates major consequences of
increased intracellular levels of ROS. Depending on the actual levels of intracellular ROS, the cell response may be limited to
increased redox signaling (as exerted by redox-dependent modulation of several signaling components) and upregulation of
antioxidant defenses (i.e., the so-called antioxidant response). Excess generation of intracellular ROS may lead to cell injury
and death. More details can be found in the text.
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PEPCK (122, 130). Although NAFLD is characterized by hy-
perinsulinemia, under conditions of oxidative stress, as ob-
served in NASH (43), FOXO1 becomes unresponsive to
insulin because of interaction with the deacetylase sirtuin-1,
resulting in induction of gluconeogenic genes (61, 131). The
role of FOXO1 is supported by a recent study performed in
control subjects and in patients with NAFLD or NASH (189),
where it was found that: 1) expression of PEPCK is higher in
patients with NASH than in those with simple NAFLD or
normal liver, and was correlated with insulin resistance; 2)
FOXO1 mRNA levels are higher in NASH and correlate with
PEPCK; 3) in the presence of oxidative stress FOXO1 upre-
gulation in steatohepatitis is associated with decreased Ser256
phosphorylation, with decreased Akt1 and increased JNK-1
activity.
Several kinases other than JNK-1 have been reported to be
involved in insulin resistance as a possible consequence of
increased generation of ROS and/or reactive nitrogen species
(RNS) in response to a variety of stimuli, including hyper-
glycemia, elevated FFAs, or cytokines (52, 79). A critical ex-
ample is represented by IjB kinase beta (IKKb), a well known
stress-sensitive kinase that controls the activation of NF-jB.
Similar to other kinases, activated IKKb phosphorylates IRS-1
on Ser307 residue, resulting in inhibition of insulin action (63).
Interestingly, inhibitors of IKKb such as salicylate, or ligands
of peroxisome proliferator-activated receptor-c (PPAR- c) can
restore insulin sensitivity (94, 208). Moreover, IKKb ( +/-)
mice are more insulin-sensitive when compared to their con-
trol littermates (94, 208). In addition, treatment of a limited
number of type 2 diabetes patients with high dose of aspirin
resulted in reduced hepatic glucose production and fasting
hyperglycemia as well as in increased insulin sensitivity (52).
Other kinases reported to be involved in oxidative stress-
induced insulin resistance include p38 mitogen-activated
protein kinase (p38MAPK), whose activation by oxidative
stress inhibits insulin-stimulated glucose transport, as well as
activation of mTOR, of several PKC isoforms (mainly PKCh
and PKCd) and salt-inducible kinase 2 (SIK2) (reviewed in
Ref. 52).
The action of adiponectin, a ‘classical’ adipokine, offers
another example of a link between oxidative stress and insulin
signaling. In the liver, adiponectin leads to AMPK phos-
phorylation that in turn causes decreased expression of genes
involved in gluconeogenesis (e.g., glucose-6-phosphatase,
PECK) and lipogenesis (e.g., SREBP-1) resulting in decreased
hepatic glucose production and TG content. Adiponectin has
also been reported to increase glycogen synthesis and aerobic
consumption of glucose, and to exert an insulin-mimetic ac-
tion that has been related to intracellular generation of ROS
(58). Exposure of hepatocytes to globular adiponectin leads to
a transient generation of ROS through activation of the small
GTPase Rac1 and 5-lipoxygenase (5-LOX) (37, 133). This in-
tracellular burst of ROS leads to ligand-independent trans-
activation of IR through oxidation and inactivation of PTP1B,
a phosphotyrosine phosphatase controlling IR phosphoryla-
tion. In addition, ROS mediate the downstream response to
both globular adiponectin and insulin, including activation of
the MAPK cascade and ERK1/2 (58). However, insulin-me-
diated generation of ROS is related to NADPH-oxidase and
not to 5-LOX. This form of redox signaling, based on revers-
ible oxidation of PTPs, represents a strategy adopted by cells
to reinforce receptor tyrosine kinase (RTK) signaling by
avoiding inactivation by PTPs and has been described to
parallel activation of many RTKs (37, 38, 133). These redox-
related and insulin-mimetic mechanisms help to understand
the in vivo effects of adiponectin on the liver (19, 212) and the
muscle (33).
Adipokines, Oxidative Stress, and Inflammation
in Fatty Liver
Several studies have addressed the impact of adipokines on
the development of hepatocellular damage and inflammation,
two major components of steatohepatitis. In most of these
studies, a tight relation between adipokine expression and
oxidative stress has been found. As circulating levels of adi-
pokines have been shown to have an impact on the devel-
opment of steatohepatitis, the relationships between oxidative
stress and mechanisms of adipokine secretion in the adipose
tissue are also briefly discussed.
Leptin
Leptin levels are usually elevated in obese patients, and
have been found to correlate with systemic parameters of
oxidative stress, suggesting that oxidative stress may con-
tribute to adipokine imbalance in these subjects, especially in
the presence of diabetes (164, 198). Leptin, like adiponectin,
controls fat catabolism and glucose production activating
central neural pathways and increasing hepatic AMPK ac-
tivity (10, 137). However, the observation that steatosis is
associated with elevated leptin levels in obesity indicates the
presence of hepatic leptin resistance. The mechanisms of this
disturbance are still poorly understood, and a role of nutri-
ents, such as fructose, has recently been suggested (102, 140).
Hyperleptinemia in fructose-fed rats is associated with high
levels of tyrosine phosphorylation of STAT-3, but not of serine
phosphorylation in nuclear STAT-3, suggesting a molecular
mechanism for hepatic leptin resistance (140). Another
mechanism leading to leptin resistance in this model has been
related to increased levels of SOCS-3 and impaired phos-
phorylation on serine/threonine residues of proteins down-
stream of the leptin receptor, leading to reduced activation of
FOXO1 and AMPK (191). Appearance of leptin resistance has
also been linked to the endocannabinoid system, through
activation of the CB1 receptor (134). Regulation of leptin re-
ceptors may be an additional component contributing to
leptin resistance, as in diet-induced obesity, hepatic leptin
receptor isoforms were found to be downregulated in the liver
(25). Resistance to leptin should explain why obese patients
with high leptin have fatty liver despite the anti-steatotic ac-
tion of this adipokine.
Leptin is involved in innate and adaptive immunity. Sur-
vival and cytokine production by T-cells is promoted by
leptin, which also stimulates phagocytic activity of macro-
phages, as well as chemotaxis of polymorphonuclear cells. As
a consequence, ob/ob mice show reduced inflammation in
autoimmune disease models but are more susceptible toward
bacterial or viral infections. Leptin deficiency is associated
with increased hepatotoxicity and mortality following endo-
toxin administration (205), an effect mediated by impaired
macrophage function and cytokine imbalance (46). Con-
versely, leptin-deficient mice show less liver damage in
models of T cell-mediated hepatitis, such as that induced by
injection of concanavalin A, in association with lower levels of
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TNF-a and IL-18 (55). Thus, leptin generally acts as a proin-
flammatory agent and participates in the protection from
microbial infections. Additionally, leptin has a protecting role
in models of alcoholic liver damage (13, 181). A possible
mechanism underlying this action is the prevention of etha-
nol-elicited cytotoxicity and apoptosis, which was associated
with decreased levels of reactive oxygen species (ROS) and an
increase in antioxidant protective pathways (13). Conversely,
leptin has also been involved in the generation of oxidative
stress. Malondialdehyde levels in the liver of mice treated
with a high fat diet were found to be directly related to cir-
culating leptin levels, and leptin expression was upregulated
in liver tissue (125).
Adiponectin
Oxidative stress is a relevant step regulating adiponectin
secretion at the level of adipose tissue. In general, oxidative
stress inhibits adiponectin secretion, linking adipose tissue
inflammation, generation of reactive oxygen species, and
downregulation of adiponectin secretion (62, 141). These data
have been recently extended to children, where obesity-
associated oxidative stress was inversely related to the levels
of high-molecular weight adiponectin, the more metabolically
active complex (11).
The mechanisms leading from adipose tissue expansion in
obesity to oxidative stress and reduced adiponectin secretion
are complex (Fig. 7). In rats, administration of angiotensin II
results in hypertension and endothelial dysfunction, together
with a decrease in adiponectin levels and in expression of
adiponectin mRNA in the adipose tissue (68). These effects
were inhibited by co-treatment with antioxidants, which also
reduced angiotensin-mediated upregulation of NADPH oxi-
dase. These results are relevant also to the pathogenesis of
steatohepatitis and liver fibrosis, where the renin-angiotensin
system plays a pivotal role (15). Interestingly, hydrogen per-
oxide was found to inhibit adiponectin expression in cultured
adipocytes, confirming the negative modulation by oxidative
stress (68, 89). The mechanisms underlying inhibition of adi-
ponectin expression by ROS were further investigated in re-
lation to the activity of uncoupling protein-2, which induces
adiponectin, while inhibitors of mitochondrial respiration
suppress it in a ROS-dependent fashion (36). The inhibition of
adiponectin expression by ROS was mediated by upregula-
tion of CHOP-10, which interferes with binding of C/EBPb to
the adiponectin promoter.
High glucose levels may be another factor leading to adi-
pokine imbalance, including reduced adiponectin expression.
Exposure of 3T3-L1 adipocytes to constant or intermittent
high glucose suppressed the expression of adiponectin, and
increased that of resistin in mature adipocytes, compared to
normal glucose conditions. These actions were accompanied
by increased levels of oxidative stress-related products and
nitrotyrosine and were reverted by antioxidants (170). Along
these lines, derangements in mitochondrial function have
been identified as an additional mechanism relevant to adi-
ponectin expression in the adipose tissue. Adiponectin ex-
pression and mitochondrial content in adipose tissue were
reduced in obese db/db mice, while in cultured adipocytes,
impairment in mitochondrial function decreased adiponectin
synthesis (98). More recently, the same group demonstrated
that endothelial NO synthase (eNOS) plays an important role
in adiponectin synthesis by producing NO and enhancing
mitochondrial function in adipocytes (97). Plasma adipo-
nectin concentrations were reduced in eNOS knock-out mice,
and this was associated with decreased expression of mi-
tochondrial biogenesis factors, and increased levels of 8-
hydroxyguanosine, a biomarker of oxidative stress. NO
played a pivotal role, as chronic administration of a NO donor
to eNOS-deficient mice increased both plasma adiponectin
and adiponectin expression in adipose tissue. Generation of
oxidative stress may even overshadow the beneficial effects of
weight loss on adiponectin secretion. In subjects with acute
weight reduction, increased urinary excretion of molecules
related to oxidative stress was accompanied by a decrease in
serum adiponectin (203).
Importantly for the pathogenesis of liver injury, ethanol has
been shown to reduce the expression of adiponectin in the
adipose tissue (34). The decrease in circulating adiponectin
caused by chronic alcohol exposure was associated with in-
creased homocysteine, while betaine reduced homocysteine
and improved adiponectin (163). Accordingly, supplementa-
tion with taurine in a rat model of alcoholic liver injury re-
sulted in normalization of serum levels of adiponectin and of
its gene expression at the adipose tissue level, and in reduc-
tion of fat accumulation in the liver (35). As a mechanism,
taurine prevented the decrease in C/EBP-alpha and PPAR-
alpha, which regulate adiponectin expression, in response to
ethanol administration. Similarly, treatment with mulberry
leaf, which blocks experimental atherosclerosis, was recently
shown to increase the expression of adiponectin, and to de-
crease that of TNF-a, MCP-1, and macrophage markers in
white adipose tissue (169). These actions were associated with
FIG. 7. Mechanisms of reduced adiponectin secretion
involving oxidative stress. Generation of reactive oxygen
species (ROS) within the adipocyte leads to reduced gene
expression and secretion of adiponectin. Increased ROS
production may be triggered by ethanol consumption, an-
giotensin II, or high glucose levels. In contrast, mitochondrial
function reduces oxidative stress, partly due to the action of
uncoupling protein 2 (UCP2). Reduction of ROS production
is favored by eNOS expression, via production of NO, which
increases mitochondrial biogenesis. ROS act on adiponectin
gene expression by increasing the abundance of CHOP-10,
which forms a complex with C/EBPb, preventing its binding
to the adiponectin promoter.
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reduced expression of NADPH oxidase in both adipose tissue
and the liver. In ethanol-induced steatosis, resveratrol, a
polyphenol with antioxidant properties, is another factor that
limits fat accumulation and leads to increased adiponectin
secretion (6). Nonetheless, in some models, adiponectin re-
lease may be positively regulated by oxidative stress. For
example, downregulation of aldehyde oxidase-1 was associ-
ated with reduced adiponectin secretion (194).
Activation of PPAR-c has emerged as an additional pivotal
regulator of adiponectin expression and action. Thiazolidi-
nediones, synthetic PPAR-c ligands with antidiabetic effects,
increase adiponectin levels in humans and induce its expres-
sion in experimental models (111). The tissue protective ef-
fects of thiazolidinediones are linked to both adiponectin
induction and protection from oxidative stress, as exemplified
in a model of ischemic heart disease (176). Targeted deletion
of PPAR-c in the adipose tissue, and studies on the adipo-
nectin promoter sequence have confirmed the critical role of
this transcription factor in the induction of adiponectin ex-
pression (69) (81).
More recently, additional data have indicated that part of
the metabolic actions of thiazolidinediones may be mediated
through PPAR-c-dependent modulation of adiponectin re-
ceptor expression in different tissues, including the liver. In
HepG2 cells, Sun et al. showed that rosiglitazone, a thiazoli-
dinedione, increases the mRNA and protein levels of Adi-
poR2, the predominant adiponectin receptor in hepatocytes
(171). These actions were confirmed by in vivo studies, where
the hepatic levels of AdipoR2 were increased in mice treated
with rosiglitazone. Along these lines, modulation of adipo-
nectin receptor expression may have a relevant impact in the
pathogenesis of both alcoholic and nonalcoholic steatohepa-
titis. In a mouse model of alcoholic hepatic steatosis, admin-
istration of rosiglitazone resulted in increased circulating
levels of adiponectin and upregulated expression of both
AdipoR1 and AdipoR2 in the liver (158). Remarkably, these
changes were associated with activation of the sirtuin 1–
AMPK pathway, and resulted in an amelioration of steatosis.
Similarly, in rats administered a high-fat diet, as a model of
nonalcoholic fatty liver disease, rosiglitazone improved his-
tology and increased the expression of AdipoR1 and AdipoR2
in liver and visceral fat (109).
Adiponectin has in general a hepatoprotective and anti-
fibrogenic effect in the liver wound healing process. In ex-
perimental steatohepatitis, administration of adiponectin
ameliorates liver hepatomegaly, steatosis and necro-inflam-
mation, through induction of hepatic fatty acid oxidation and
inhibition of fatty acid synthesis (199). Accordingly, in obese
mice subjected to damage by galactosamine/LPS, adipo-
nectin administration protected from injury, reducing TNF
and increasing PPAR-a (120). In addition, consumption of diet
rich in saturated fat, which protects from alcoholic liver
damage, increases adiponectin secretion (207). Although
adiponectin and leptin share their effects as factors counter-
acting ectopic fat deposition, they have divergent effects on
inflammation. In fact, while leptin-deficient mice are pro-
tected from T cell-mediated hepatitis, lipodystrophic mice
that lack both adiponectin and leptin are not, unless adipo-
nectin is administered (155). In general, adiponectin reduces
inflammation, stimulating secretion of anti-inflammatory cy-
tokines (e.g., IL-10), blocking NF-jB activation, and inhibiting
release of TNF-a, IL-6, and chemokines (179). Conversely,
inflammation blocks adiponectin secretion, and specifically,
adipose tissue inflammation contributes to reduce plasma
adiponectin levels in obesity. Adiponectin protects also
against Fas-mediated hepatocyte death (193). Therefore, adi-
ponectin may be envisioned as a negative modulator of sys-
temic and hepatic inflammation that characterizes the
metabolic syndrome (66). Nonetheless, hepatic damage trig-
gered by lipotoxicity may occur in spite of increases in adi-
ponectin levels. In mice with steatohepatitis, antisense
oligonucleotides interfering with diacylglycerol acyltransfer-
ase 2 decreased hepatic steatosis, but increased hepatic free
fatty acids, lipid peroxidation, necroinflammation, and fi-
brosis. Progression of liver damage occurred despite reduced
hepatic expression of tumor necrosis factor a and increased
serum adiponectin (201). A similar dissociation between
steatosis and steatohepatitis has been shown in a recent study
where a diet deficient in methionine and choline was ad-
ministered to mice defective in thioredoxin-binding protein-2
(TBP-2), an endogenous negative regulator of the antioxidant
molecule, thioredoxin. These mice showed severe simple
steatosis rather than steatohepatitis, and oxidative stress in-
flammation and hepatic fibrosis were attenuated in TBP-2(-/-)
mice (5). These studies clearly indicate that fatty infiltra-
tion and steatohepatitis may be dissociated, and only the
‘inflammatory’ forms may progress to fibrosis.
Adiponectin modulates generation of oxidative stress-re-
lated products (Fig. 8). Initial evidence was provided by
Yamauchi et al., who cloned the AdipoR1 and R2 receptors
and showed their ability to downregulate oxidative stress in
the liver and adipose tissue (202). The molecular mecha-
nisms by which this action of adiponectin is exerted are still
unclear. In fatty liver, adiponectin downregulated hepatic
expression of the enzyme aldehyde oxidase 1, which de-
toxifies aldehydes and generates oxidative stress (132). This
effect was dependent, at least in part, on upregulation of
PPAR-a, thus providing a link between the metabolic actions
of this adipokine and regulation of the oxidative balance. In
skeletal muscle, adiponectin was found to induce a number
of NF-jB related genes, including ferritin heavy chain, which
together with manganese superoxide dismutase is respon-
sible for the protection from oxidative stress mediated by
this adipokine (76). The antioxidant effects of adiponectin
have been recently linked also to activation of AdipoR1 and
the resulting downstream release of intracellular calcium
together with increased activation of AMPK and sirtuin-1
(80). In macrophages, adiponectin modulates the response to
lipopolysaccharide dependent on toll-like receptor-4, which
leads to TNF-alpha secretion and generation of reactive ox-
ygen species (75). Interestingly, this effect, which is mediated
by expression of interleukin-10, occurs after an initial phase
during which adiponectin actually increases TNF-a expres-
sion, indicating a complex action of adiponectin on the
pathways regulating inflammation. Along these lines, in
steatotic liver undergoing ischemia-reperfusion, adiponectin
siRNA confer protection against oxidative stress and injury
(121).
In line with these results, increase in hepatic steatosis and
aminotransferase was observed in mice deficient for adipo-
nectin, together with increase in thiobarbituric acid reactive
substances, decrease in glutathione levels and expression of
antioxidant enzymes (53). It is still unclear to what extent
AMPK activation participates in the antioxidant action of
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adiponectin in steatohepatitis. A study recently performed in
a model of ischemia-reperfusion myocardial injury suggests
that AMPK does indeed participate in protection against is-
chemia/reperfusion injury, but adiponectin still provides
cardioprotection even after interference with AMPK activa-
tion (192). More important, treatment of mice defective in
AMPK with adiponectin reduced oxidative stress to the same
extent as in WT mice. In addition, it has been reported very
recently in the same model that in mice made diabetic by
administration of a high fat diet, the ability of adiponectin to
activate AMPK is blunted, thus providing an additional
mechanism for reduced cardioprotection and limitation of
oxidative stress in diabetes (206). It still remains to be deter-
mined to what extent these data are applicable in the context
of steatohepatitis.
Resistin
A limited number of studies have investigated the rele-
vance of resistin in the pathophysiology of NAFLD. Im-
provement or worsening of hepatic insulin resistance was
observed by reducing or increasing resistin levels, respec-
tively (128, 146). The effects on the liver are also mediated
centrally, as administration of resistin into the third cerebral
ventricle stimulates glucose production independent of cir-
culating levels of glucose-controlling hormones (127). Re-
duced hepatic glucose production in the absence of resistin is
also associated with higher hepatic AMPK activation (14).
Hepatic steatosis and VLDL secretion are decreased in re-
sistin-deficient mice placed on a high-fat diet, suggesting a
role of resistin in the induction of steatosis (160).
Additional studies link the biology of resistin with hepatic
inflammation. In rats, resistin administration significantly
worsens inflammation induced by LPS injection (16). In hu-
mans, resistin is expressed within the liver during severe
damage, including the one associated with NASH, and cor-
relates with infiltration of inflammatory cells (22). In rats, re-
sistin administration significantly worsens inflammation after
LPS injection, through the involvement of the coagulation
cascade (16). In addition, in a model of cirrhosis, higher gene
and protein expression of resistin and TNF-a was observed in
epididymal fat, and TNF injection upregulated resistin (107).
Expression of resistin has been documented in quiescent HSC,
while activated human HSC respond to resistin with in-
creased expression of pro-inflammatory chemokines and NF-
jB activation (22, 157). Resistin expression has been linked to
adipose tissue oxidative stress in humans (161). Support to
this hypothesis is also provided by the recent observation that
uremia increases the expression of resistin and retinol binding
protein 4 via increased generation of oxidative stress in the
adipose tissue and in isolated adipocytes (42).
Other adipokines
Adipose tissue is a source of a high number of factors,
some of which are produced at high levels in other tissues,
including the liver. The role of many of these factors in the
pathogenesis of insulin resistance and in the development of
steatosis and steatohepatitis has been the focus of recent
reviews. In light of the limited data on oxidative stress, or for
the presence of recent and comprehensive reviews, only a
brief mention of the role of these molecules will be made
herein.
TNF-a is a well-known pro-inflammatory cytokine that is
abundantly released by adipose tissue. In addition to what
described in previous sections of the present review, the
action of TNF-a is intimately related to the upregulation of
intracellular generation of ROS and then of oxidative stress
(72, 133, 177–179). Hotamsligil et al. linked for the first time
TNF-a to obesity, insulin resistance, and chronic inflamma-
tion (74), describing described significant elevation of TNF-a
in adipose tissue of db/db mice. Following that seminal study,
several other reports have progressively increased our
knowledge on the role of TNF-a in relation to adipose tissue
and hepatic NAFLD/NASH. In aggregate, the data sum-
marized below suggest that TNF-a plays important roles in
FIG. 8. Adiponectin reduces oxidative
stress in different cellular targets. In he-
patocytes, binding of adiponectin to its cog-
nate receptors leads to activation of aldehyde
oxidase-1 (AOX-1), which reduces intracel-
lular levels of reactive oxygen species (ROS),
possibly through increased activation of
peroxisome proliferator-activated receptor
(PPAR)-a. In macrophages, adiponectin in-
creases the expression of the anti-inflamma-
tory cytokine, interleukin-10 (IL-10). IL-10
blocks the generation of tumor necrosis factor
(TNF) in response to activation of toll-like
receptor-4 (TLR-4) by lipopolysaccharide. In
skeletal muscle, adiponectin activates nu-
clear factor-jB that results in increased ex-
pression of the ferritin heavy chain (FHC)
and of manganese superoxide dismutase
(MnSOD). In addition, activation of AdipoR1
generates an increase in intracellular calcium
that in turn is responsible of activation of
AMP-activated protein kinase (AMPK) and
of sirtuin-1. All these modifications result in
reduced accumulation of ROS.
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the progression of NAFLD, including hepatic inflammation
and fibrogenesis.
1. Adipose tissue of obese individuals is characterized by
increased infiltration of macrophages and so-called
‘‘hypertrophied’’ adipocytes (195), the latter being able
to release large quantities of free fatty acids (FFA) via
macrophage-induced adipocyte lipolysis. FFA can serve
as naturally occurring ligands for Toll-like receptor-4
(167, 168), and FFA increase the production of TNF-a in
macrophages through a TLR4/ NFjB pathway, thus
establishing a vicious cycle.
2. In the liver, Kupffer cells are the main producer of TNF-
a, in a LPS-induced manner. In animal models, activa-
tion of Kupffer cells leads to induction of the TNF-a/
TNF receptor signaling pathway, which, as mentioned
in the previous section, is critically involved in the
pathogenesis of liver fibrosis in NASH (183). Along
these lines, ob/ob are known to overexpress TNF-a (106)
and indeed in these animals, treatment with anti-TNF
antibody results in a significant improvement of
NAFLD as a consequence of two major events: a) in-
hibition of c-Jun N-terminal kinase activity (involved in
promoting insulin resistance), and b) decreased DNA
binding activity of NFjB (involved in the acceleration/
amplification of inflammatory response).
3. In humans, TNF-a levels are significantly increased in
both NAFLD and NASH. Moreover, TNF-a levels cor-
related with hepatic fibrosis in NASH patients (82),
with gene expression of both TNF-a and of its receptor
being significantly elevated both in hepatic and adipose
tissues of human NASH patients (40). Accordingly, se-
rum TNF-a levels have been confirmed to significantly
correlate with NAFLD activity score (NAS) (114), a
histologic scoring system that is becoming a standard
reference in the grading of inflammation and damage in
NAFLD. Along these lines, polymorphisms in the TNF-
a promoter region and serum level of soluble TNF re-
ceptor 2 have been shown to correlate significantly with
progression of NAFLD in human patients (180). Finally,
the administration of the TNF-a inhibitor pentoxifylline
was found to improve amino-transferase serum levels
and the insulin resistance index assessed by homeo-
static metabolic assessment (HOMA-IR) in NASH pa-
tients (2, 145).
Plasminogen activator inhibitors (PAI) decrease fibrinolytic
activity by acting as rapid inhibitors of both tissue plasmin-
ogen activator (tPA) and urokinase-type plasminogen acti-
vator. Both the liver and the adipose tissue are major
contributors to production of PAI-1 in humans (54). Insulin,
very low-density lipoprotein, and free fatty acids induce PAI-
1 production by the liver. In addition, PAI-1 is expressed by
HSC and contributes to fibrogenesis (211).
PAI-1 expression in adipose tissue is upregulated in
obesity (50), and hyperinsulinemia leads to increased PAI-1
plasma levels and gene expression (142). In addition, mod-
ulators of inflammation contribute to upregulation of PAI-1,
which is an acute-phase protein. TNF-a, a pro-inflammatory
cytokine overexpressed in adipose tissue, is another critical
regulator of PAI-1 production (143). Different studies have
demonstrated the presence of hypoxia in adipose tissue in
conditions of obesity (47), and hypoxia leads to increate
secretion of PAI-1 and decreased adiponectin secretion by
adipocytes (70).
Several lines of evidence link generation of oxidative stress
and expression of PAI-1 in adipose tissue and different tissues
that develop chronic damage (8, 47). In adipocytes, high
glucose and advanced glycation end products upregulated
PAI-1 expression by oxidative stress-dependent pathways
(186). Moreover, oxidative stress and PAI-1 secretion were
inhibited by blockers of the renin-angiotensin system, a well-
known mediator of adipokine imbalance (101).
In the liver, alcohol-related damage may be prevented, at
least in part, by interference with PAI-1 (12). Moreover, up-
regulation of PAI-1 expression by alcohol in endothelial cells
is inhibited by limitation of oxidative stress (162). PAI-1 has
also been implicated in fibrogenesis, and in murine embryo
fibroblasts the induction of PAI-1 by TGF-b, a profibrogenic
cytokine, was mediated by activation of NADPH oxidase 4
and the resulting generation of ROS (108). This pathway
causes increased activation of JNK and p38MAPK due to in-
activation of MAPK phosphatase 1.
Monocyte chemoattractant protein-1 (MCP-1) is a proin-
flammatory chemokine that regulates migration of monocytes
and lymphocytes. Hepatic expression of MCP-1 is regulated in
different conditions of liver injury, and studies in genetically
modified animals have identified protective or detrimental
roles of this chemokine in various experimental conditions
(209). Hepatic MCP-1 expression is also increased in patients
with NAFLD, where it correlates with liver fat. This has led to
the hypothesis that MCP-1 may be a critical regulator of the
changes that are associated with NAFLD and the metabolic
syndrome (20). Experimentally, interference with CCR2, the
main receptor targeted by MCP-1, reduces metabolic alter-
ations and fatty infiltration of the liver in lipoatrophic mice or in
a mouse model of type 2 diabetes (172, 204). At least part of
these effects are mediated by recruitment of inflammatory cells
to adipose tissue, as indicated by studies in which conditional
deletion of MCP-1 in adipose tissue was obtained (90). MCP-1
derived from the adipose tissue has also been shown to directly
induce accumulation of lipids in hepatocytes (39).
Several lines of evidence link oxidative stress and MCP-1
expression in adipose tissue. Besides regulating the expres-
sion of adiponectin (see above), the antioxidant mulberry leaf
inhibits expression of MCP-1 in white adipose tissue (169). In
addition, angiotensin receptor blockade was associated with
lower MCP-1 expression and generation of oxidative stress
(105).
In the liver, a direct link between MCP-1 expression and
generation of oxidative stress has been recently demonstrated
in an acute model of hepatic damage (209). Hepatic stellate
cells are responsible for a significant proportion of MCP-1
expression in the liver, and also in this case oxidative stress
has been shown to promote expression of this chemokine (118,
200). Importantly, MCP-1 may be profibrogenic not only
through its proinflammatory actions, but also directly, tar-
geting activated stellate cells (119).
In humans, visfatin is increased in association with type 2
diabetes and the metabolic syndrome (137). Recently, visfatin
has been identified as a circulating nicotinamide phosphor-
ibosyltransferase, which catalyzes formation of nicotinamide
mononucleotide and may influence the function of sirtuins
(126). Along these lines, oxidative stress was found to reduce
the expression of both sirtuins and visfatin in a monocytic cell
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line (44). A role of visfatin in inflammation has also been
suggested, and in a group of patients with NAFLD, plasma
concentrations of visfatin could predict the presence of portal
inflammation (9).
Chemerin regulates glucose uptake in adipocytes and
stimulates lipolysis (65), and its serum levels are related to
body mass index and the metabolic syndrome (24). In patients
with NAFLD, chemerin levels were found to be elevated and
to correlate with the NASH activity score (100). Chemerin has
been associated with the induction of inflammation (51), and
its possible relation with oxidative stress deserves future
evaluation.
Adipokines, Oxidative Stress, and HSC Biology
Several in vitro and in vivo studies demonstrate a pro-
fibrogenic role for leptin. Absence of leptin or leptin receptor
signaling, as occurring in ob/ob mice, and fa/fa rats respectively,
markedly reduces the development of fibrosis in different ex-
perimental models of liver injury, including thioacetamide in-
toxication, chronic CCl4 administration, or experimental NASH
(78, 104). Whereas deficiency of leptin reduces fibrogenesis,
injection of recombinant leptin during acute or chronic liver
injury upregulates fibrogenic pathways (77). Conversely,
administration of a leptin antagonist, or its co-administration
together with recombinant leptin in a model of thioacetamide-
induced fibrosis, markedly improves survival (49).
Leptin modulates the biology of different cell types which
participate in the liver response to injury, such as Kupffer
cells, sinusoidal endothelial cells, and activated HSC. Leptin
increases phagocytic activity and cytokine secretion by
Kupffer cells and macrophages (46) and stimulates endothe-
lial cells to proliferate and to produce reactive oxygen species
(138). Several groups have shown that leptin exerts direct
actions on HSC, which express functionally active leptin re-
ceptors (7, 149, 151). Leptin modulates genes regulating ex-
tracellular matrix deposition and degradation in HSC (31, 149,
173), and in addition, it modulates proliferation and survival,
via activation of different intracellular signaling pathways
(151), and contributes to amplify the inflammatory response,
via NF-jB activation (7). More recently, it has been shown that
leptin enhances phagocytosis of apoptotic bodies by HSC (84),
an event associated with HSC activation and fibrosis pro-
gression (210).
Recent studies have also investigated the intracellular sig-
naling pathways involved in leptin-induced HSC activation
and the role of oxidative stress in this context (Fig. 9). As with
other cytokine receptors, generation of oxidative stress-
related molecules participates in propagation of intracellular
signaling. Exposure of LX-2, an immortalized human hepatic
stellate cell line, to leptin, increases the intracellular levels of
H2O2 in a Jak2-mediated fashion, contributing to the upre-
gulation of TIMP-1 and type I procollagen (29, 31). Moreover,
leptin was found to repress the basal level of MMP-1 mRNA
and its promoter activity, an action again dependent on Jak2-
mediated, H2O2-dependent, activation of ERK1/2 and
p38MAPK (30). An example of the relevance of leptin-induced
oxidative stress for the biology of HSC is provided by the
effects of curcumin, which was able to block signaling
downstream of the ObRb receptor interfering with ROS gen-
eration (174).
More recently, De Minicis et al. (45) showed that NADPH
oxidase is a crucial mediator of the proliferative, fibrogenic,
and inflammatory actions of leptin in HSC. Pharmacologic or
genetic inhibition of NADPH resulted in reduction of the
ability of leptin to induce HSC proliferation and upregulation
of fibrogenic and inflammatory molecules (45). In addition,
other data provide evidence that exposure of rat HSC to leptin
results in the inhibition of the expression and activity of per-
oxisome proliferator-activated receptor-c (PPARc) (213),
which maintains HSC quiescence and reverses HSC trans-
differentiation to myofibroblasts.
An additional action of leptin that is relevant to the fibro-
genic process is the modulation of hepatic angiogenesis. Ac-
FIG. 9. Involvement of reactive oxygen
species generation in leptin receptor
signaling in hepatic stellate cells. Acti-
vation of the ‘long form’ of leptin recep-
tor, ObRb, results in activation of the
nonreceptor tyrosine kinase Jak-2, which
activates Stat3 and NADPH oxidase,
which leads to ROS generation. ROS
contribute to the downstream activation
of ERK-1/2 and of Akt. Stat3-dependent
and independent signals control a num-
ber of biological actions that are pivotal
for the actions of HSC in wound healing.
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tivation of leptin receptors in HSC leads to upregulated ex-
pression of vascular endothelial growth factor, a potent
inducer of neovessel formation (7). In addition, leptin exerts
a direct angiogenic action on endothelial cells (159). Sti-
mulation of neovessel formation in the liver by leptin is
consistent with its profibrogenic role, as angiogenesis is a
relevant component of chronic wound healing (190). Recent
data indicate the involvement of oxidative stress also in this
context (6a). On the other hand, the well-established asso-
ciation between angiogenesis and tumorigenesis suggests a
possible additional role of leptin in liver cancer. Along these
lines, recent data implicate leptin in the progression of he-
patocellular carcinoma (HCC), as leptin increases growth,
migration, and invasiveness of HCC cell lines (150). Ad-
ditionally, leptin stimulates proliferation and metastatic
potential of cholangiocarcinoma cells (56). In agreement
with these data, lack of leptin is protective in a model of
experimental steatohepatitis that leads to development of
preneoplastic foci in the liver (96).
The ability of leptin to modulate biological actions through
oxidative stress is not limited to the field of hepatic fi-
brogenesis, but has been involved in the development of
atherosclerosis, another condition characterized by altered
wound repair. In obese patients, phagocytic NADPH oxidase
activity positively correlates with leptin and with carotid in-
tima-media thickness, suggesting that hyperleptinemia may
contribute to increased NADPH oxidase activity and early
atherosclerosis (60). Leptin infusion in rats results in increased
arterial pressure and endothelial dysfunction, two features
which are relevant to the metabolic syndrome and to the
pathogenesis of atherosclerosis. In aortic and renal tissue, the
effects of leptin are mediated by elevation of oxidative stress-
related products, including activation of NADPH oxidase
(197). In addition, chronic hyperleptinemia reduces the ex-
pression of paraoxonase 1, an antioxidant enzyme contained
in plasma lipoproteins (18). Of note, reduction of leptin-in-
duced oxidative stress by antioxidant treatment also pre-
vented the decrease in paraoxonase-1 (17). Along these lines,
endothelial cells represent an additional target of the pro-
atherogenic action of leptin, where oxidative stress may be
involved. In these cells, leptin increased generation of ROS
and activated JNK, resulting in increased expression of the
proinflammatory chemokine, MCP-1 (23).
A direct antifibrotic effect of adiponectin has been
demonstrated in rodents undergoing toxic liver damage,
independent of the metabolic actions of this adipokine.
Adiponectin knockout mice developed more extensive fi-
brosis after chronic CCl4 intoxication, compared to wild-
type animals (88). These effects are mediated at least in
part by modulation of the activated phenotype of HSC,
which express both adiponectin receptors (48). Full-length
or globular adiponectin suppress multiple pro-fibrogenic
actions of HSC (21), and activation of AMPK has been
recently identified as a pivotal mechanism in this context
(1, 27). AMPK activation occurs downstream of AdipoR1,
but interference with AdipoR2 signaling has been recently
shown to be sufficient to block the progression of experi-
mental steatohepatitis (182). Adiponectin knockout mice
develop more extensive fibrosis than wild-type animals
after chronic CCl4 intoxication, demonstrating that adipo-
nectin has antifibrogenic effects independently of metabolic
actions (88).
Appearance of hepatocellular carcinoma is a well-estab-
lished consequence of fibrogenic liver diseases, and additional
information has recently become available on the role of
adiponectin in liver cancer. Administration of a choline-defi-
cient, amino acid-defined diet to adiponectin-deficient mice
resulted in increased incidence of liver tumors, together with
increased levels of oxidative stress (87). In addition, lack of
adiponectin was found to delay liver regeneration (53). In an
orthotopic liver tumor model in nude mice, injection of ade-
novirus encoding adiponectin inhibited tumor growth, and
was associated with lower appearance of distant metastases
(113). These effects were accompanied by reduced activation
of hepatic stellate cells and angiogenesis. Very recently, Sax-
ena et al. (148) have shown that in hepatocellular carcinoma
cells adiponectin increases apoptosis, inducing JNK phos-
phorylation. In addition, adiponectin-mediated increase in
AMPK phosphorylation is a critical event for the induction of
JNK phosphorylation and the biological effects of adipo-
nectin. In parallel, knockout of JNK1 was found to protect
from experimental steatohepatitis and to result in elevated
adiponectin levels, thus demonstrating the complex role
played by this mitogen-activated protein kinase in the context
of adipokine biology and the pathogenesis of steatohepatitis
(152).
Perspectives
The field of adipokines has witnessed a tremendous ex-
pansion in the last 5 years, and has led to the recognition of the
role of adipose tissue and its products in several chronic dis-
eases, including those affecting the liver. In addition, evidence
for a cross-talk between adipokine biology, inflammation,
oxidative stress, and tissue repair has been provided in sev-
eral tissues in conditions of chronic damage.
In spite of the data that have accumulated, several points
still await further clarification with experimental studies. In
particular, the dual role of reactive oxygen species as intra-
cellular signaling molecules and products accumulating
during injury, make it difficult to reach general conclusions.
Areas that will need additional investigation include: (a)
elucidation of the role of oxidative stress in the context of
chronic inflammation as a mediator of insulin resistance, as
opposed to its action in the signaling cascade downstream of
insulin receptor activation; (b) evaluation of the reasons why
an approach with antioxidants, that is successful in animal
models, has been still poorly validated in humans with insulin
resistance and/or fatty liver; (c) detailed investigation of the
role played by oxidative stress in mediating the response of
the liver to adipokines, especially in the context of the an-
giogenic role of leptin and the anti-inflammatory and hepa-
toprotective role of adiponectin. As numerous laboratories are
focused on the significance of this intriguing group of mole-
cules, novel data are likely to be available very soon.
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5-LOX¼ 5-lipoxygenase
AMPK¼AMP-activated protein kinase
ChREBP¼ carbohydrate response element-binding
protein
eNOS¼ endothelial NO synthase
FFA¼ free fatty acids
FOXO1¼ forkhead box–containing protein O
subfamily-1
GSK3¼ glycogen-synthase kinase 3
HCC¼hepatocellular carcinoma
HSC¼hepatic stellate cells
IKK¼ IjB kinase
IR¼ insulin receptor
IRS¼ insulin receptor substrate
JNK¼ c-jun N-terminal kinase
LPS¼ lipopolysaccharide
MAPK¼mitogen-activated protein kinase
MCP-1¼monocyte chemoattractant protein-1
mTOR¼mammalian target of rapamycin
NAFLD¼nonalcoholic fatty liver disease
NASH¼nonalcoholic steatohepatitis
PEPCK¼phosphoenolpyruvate carboxykinase
PI3K¼phosphatidylinositol 3-kinase
PPAR¼peroxisome proliferator-activated
receptor
ROS¼ reactive oxygen species
RTK¼ receptor tyrosine kinase
SOCS¼ suppressor of cytokine signaling
SREBP-1¼ sterol regulatory element binding protein-1
STAT¼ signal transducer and activator
of transcription
TBP-2¼ thioredoxin-binding protein-2
TG¼ triglycerides
TSC¼ tuberous sclerosis complex
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